Share

 
 

Want information on dosing?

Reimbursement & patient access?

See our Approved Products

Research ADCs

Related Resources for this page:

Current research in ADCs

A new generation of ADCs may address a need for a different kind of cancer therapy1-3

Scroll over an organ below to learn about ADCs under investigation in that tumor type

Please install Flash player to use this feature
  • Despite recent breakthroughs in oncology, many cancers are still incurable. A need remains for the development of advanced therapies9,10
  • Decades of dedicated research are resulting in the capacity to create a new generation of ADCs11
  • ADCs are under investigation in many different cancer types, and recent preclinical data are emerging in support of their potential1-3
References:
1.
Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008;14:6171-6180.
2.
Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154-169.
3.
Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721-2729.
4.
Seattle Genetics website. Product pipeline. http://www.seagen.com/product_pipeline.php. Accessed October 24, 2011.
5.
Alley SC, Okeley NM, Senter PD. Antibodydrug conjugates: targeted drug delivery for cancer. Current Opin Chem Biol. 2010;14:529-537.
6.
Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2147-2154.
7.
Fayad L, Patel H, Verhoef G, et al. Blood. 2008;112(11). Abstract 266.
8.
US National Institutes of Health. ClinicalTrials.gov website. www.clinicaltrials.gov. Accessed October 26, 2011.
9.
Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. 2005;13:5043-5054.
10.
Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
11.
Ghose T, Blair AH. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J Natl Cancer Inst. 1978;61:657-676.